bpc-157 clinical trials human evidence safety and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 human clinical trials evidence

Sharabi A, Cohen E, Sulkes J, Garty M (2003) Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route

Do notwe repeat, DO NOTsquirt the water directly onto the lyophilized powder pellet

BPC 157 is a short peptide chain, and like all peptides, it is composed of small building molecules called amino acids

Published dose ranges TB-500 rodent doses in the published literature commonly include: 150 g/kg: used in some mouse studies, particularly cardiac research 2 mg per animal (absolute dose): typical low-end of absolute-dose protocols 5 mg per animal: common mid-range 10 mg per animal: common upper-range Note the convention difference: some published protocols use per-kg dosing (typical in rigorous pharmacological studies), others use absolute per-animal dosing (common in tissue-repair protocols)

Almost immediately, a large portion is converted to norcyclobenzaprine in the liver